Renal dysfunction is known to increase the risk of cardiovascular events such as acute myocardial infarction (MI). The goals of the current study were to evaluate, according to varying renal function, the diagnostic accuracy of a high-sensitivity cardiac troponin I (hs-cTnI) assay both for MI and for outcomes in patients presenting to the emergency department with symptoms suggestive of ischemia. Enrolled were 1555 consecutive patients who presented to the emergency department with clinical indications suggestive of MI, with at least two hs-cTnI measurements (UTROPIA; NCT02060760). hs-cTnI was measured on the Abbott ARCHITECT using sex-specific 99th percentile upper reference limits (URL: female 16 ng/L; male 34 ng/L). MI was adjudicated along universal MI guidelines. One-hundred-eighty-day mortality outcomes were determined. Renal function was defined by eGFR (mL/min/1.73m 2 ; MDRD). Categorical variables were compared using Pearson χ-square test and continuous variables were compared using the F-test. Cox model assessed mortality with respect to both renal insufficiency and cTn together. Sensitivities (0h 68%, 3h 92%, 6h 94%) and negative predictive values (NPVs; 0h 97%, 3 and 6h >99%) were not significantly affected by renal function.
However, specificities decreased with impaired renal function; ranging 90%-92% with normal renal function (eGFR ≥60; n = 1168); 68%-79% with impaired renal function (eGFR ≥30-59; n = 227); 56-60% with severely impaired renal function (eGFR <30; n = 83); 40%-42% in the dialysis group (n = 77). Positive predictive values (PPVs) also decreased with decreasing renal function; ranging 45%-57% with normal renal function, 35%-50% with impaired renal function; 29%-44% with severely impaired renal function; 15%-32% on dialysis. One-hundred-eighty-day all-cause mortality increased significantly with increasing hs-cTnI tertile (1.3%, 6.0%, 10.4%) and was significantly higher in patients with hs-cTnI greater than sex-specific URLs (11.7%) compared to patients with concentrations between their sex-specific URL and the LOD (6.2%) vs concentrations less than LOD (1.1%). In conclusion, our results suggest that renal dysfunction and dialysis treatment reduced the rule-in performance of hs-cTnI for AMI, and that mortality increased in patients with higher hs-cTnI concentrations and any level of renal dysfunction. Objective: Genomic testing by next-generation sequencing (NGS) has been growing as a diagnostic tool in pediatric neurology. In 2015, our tertiary care pediatric institution launched a 134-gene NGS test focused on the genetic diagnosis of childhood epilepsy. In this study, we surveyed one year of data and evaluated the clinical utility of the 134-gene test in pediatric epilepsy. Previous studies have focused on the diagnostic yield of genomic testing in epilepsy. This study expands on previous work by examining the subset of patients who may have had a change in therapy or management based on the test result. Methods: A retrospective review of all NGS epilepsy gene tests for 2016 was performed. Clinical significance of the variants reported was determined by a genetic counselor and pathologist. All variants were graded according to the 2015 ACMG guideline on variant classification. Benign and likely benign variants were not included in this analysis. A literature search was performed to determine which of the pathogenic/likely pathogenic (P-LP) variants had clinically utility in the management and/or treatment of the patients. Results: In all, 181 patients were identified in the study period. These patients had a total of 149 reported genetic variants. Pathogenic/likely pathogenic (P-LP) variants were identified in 17.1% (31 of 181) patients, variants of uncertain significance were identified in 74% (134 of 181), and no variants were reported (negative report) in 8.8% (16 of 181) of patients. Some patients had a combination of multiple P-LP and uncertain variants; these were all classified as patients with P-LP variants. Of the 31 patients with P-LP variants, there was a total of 35 P-LP variants. The most common P-LP variants were in CPA6 (n = 6), DHCR7 (n = 2), PRRT2 (n = 2), SCN1A (n = 2), and SCN5A (n = 2). In addition, there were single cases with P-LP variants in ARX, CDKL5, CTSD, EPM2A, FOXG1, KCNQ2, KCNQ3, KCNT1, MTHFR, PNKP, PNPO, POLG, SCN11A, SCN2A, SLC2A1, TCF4, and TSEN2. Of the 31 patients with P-LP variants, 32.3% (10 of 31) had potential clinical implications for changing the management and/or therapy based on the genes implicated: EPM2A, KCNQ2, KCNQ3, KCNT1, PNPO, POLG, PRRT2, and SCN1A. Conclusions: A one-year retrospective evaluation of pediatric epilepsy patients tested with a 134-epilepsy gene NGS panel yielded a P-LP diagnostic rate of 17.1% (31 of 181). Additionally, 32.3% (10 of 31) of the patients with P-LP variants had associated management and/or therapeutic implications from their test result. This study suggests that genomic (NGS) testing of medically refractory childhood epilepsy is not only essential for establishing a definitive etiology, but should also be considered standard of care because of the implications for management and/or therapy. Brigham and Women's Hospital, Harvard Medical School, Boston Background and Case Descriptions: Burkholderia cepacia complex (BCC) constitutes a growing and diverse group of Gram-negative, nonfermenting, and highly drug-resistant environmental bacterial species, frequently isolated from cystic fibrosis (CF) patients. BCC has also been reported as contaminants in materials widely used medically, including saline line flushes, leading to severe sepsis in immunocompromised patients. While particular BCC species are more commonly isolated in clinical settings, the species Burkholderia pyrrocinia is rarely associated with human infections. Here, we present a cluster of B pyrrocinia cases found in blood cultures of three non-CF patients admitted to the same hospital within a period of three weeks. The first patient was a 63-year-old man with advanced pancreatic cancer who presented with diarrhea, fevers, and hypotension after chemotherapy infusion. The second patient was a 41-year-old woman with metastatic adrenal cancer admitted with acute hypoxemic respiratory failure, who arrived at the hospital 17 days later. The third patient was a 65-year-old man found unconscious at home, who arrived at the hospital four days after the second patient. All three patients were found to have multiple positive blood cultures within days of arriving at the hospital. Methods: Standard microbiological techniques along with matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) were used to initially characterize the isolates. Further speciation was performed at the Cystic Fibrosis Foundation Burkholderia cepacia Research Laboratory and Repository using repetitive extragenic palindromic PCR (rep-PCR). For whole genome sequencing, we utilized the multihospital prospective genomic surveillance program run by the Massachusetts Host-Microbiome Center. Briefly, genomic libraries were prepared from total DNA extracted from each isolate using the Nextera library and sequenced by Illumina MiSeq using PE 2.5 kits. An internally developed computational pipeline of open source tools and custom scripts, deployed to the Partners ERIS cluster, was used to perform genomic assemblies, and annotate individual genes and mobile vectors, as well as for SNP-calling and tree visualization to assess strain relatedness.
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Results: All three isolates demonstrated similar phenotypic characteristics and antibiotic susceptibility profiles, and were identified using standard microbiology techniques and MALDI-TOF MS as B cepacia complex.
Rep-PCR identified all three isolates as B pyrrocinia, and strongly suggested they were the same strain. Bacterial whole genome sequencing found these isolates to have greater than 99.9% homology, providing further evidence of their relatedness. Conclusion: Although extensive investigation by our laboratory and infection control has yet to identify a common source, the phenotypic and genomic similarity of these isolates, and the infrequency of B pyrrocinia bloodstream infections, coupled with their temporal association strongly suggest a common environmental source and route of exposure prior to their presentation. Antifibrinolytic drugs such as tranexamic acid are used to prevent blood loss in many clinical situations, including trauma patients and during cardiac surgery. The goal of this study is to examine the effectiveness of tranexamic acid in preventing intraoperative blood loss during major cardiac surgery. Out
